Adeniyi Ayinde Abdulwahab, Ukamaka Gladys Okafor, Damilola Samuel Adesuyi, Adriana Viola Miranda, Rashidat Onyinoyi Yusuf, Don Eliseo Lucero-Prisno III
{"title":"非洲药品管理局和药品监管:进展、挑战和建议。","authors":"Adeniyi Ayinde Abdulwahab, Ukamaka Gladys Okafor, Damilola Samuel Adesuyi, Adriana Viola Miranda, Rashidat Onyinoyi Yusuf, Don Eliseo Lucero-Prisno III","doi":"10.1002/hcs2.117","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n <p>In response to the situation of the African healthcare system, the African Medicines Agency (AMA) was established by the African Union (AU) to regulate access to medicines and support the local manufacture of medications. This study aimed to describe the factors that enabled the establishment of the African Medicines Agency and its successes, challenges, and perceived benefits. We reviewed data sources that explored the progress and challenges of the African Medicines Agency and Medicines Regulation in Africa. The SPIDER framework was used to organise the research focus and to extract the keywords for the literature search. The study data were obtained from PubMed Central, ScienceDirect, and Google Scholar. Out of 249 studies screened, 19 were selected for this narrative review. Critical successes observed in the agency's establishment include the appointment of a Special Envoy, the selection of its headquarters, and the signing of its treaty by 37 member states. However, it is hindered by poor political commitment, differences in risk-benefits interpretation and organizational structure, weak legal and regulatory frameworks, inadequate financial mechanisms, and inadequate political and policy leadership in some member states. The value of AMA in achieving optimal health outcomes and its other benefits must be considered despite the challenges being encountered. Therefore, all member states should adopt the best procedures in signing and ratifying the treaty and implementing associated commitments to improve efficiency and accountability in African medicine regulation.</p>\n </section>\n </div>","PeriodicalId":100601,"journal":{"name":"Health Care Science","volume":"3 5","pages":"350-359"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11520252/pdf/","citationCount":"0","resultStr":"{\"title\":\"The African Medicines Agency and Medicines Regulation: Progress, challenges, and recommendations\",\"authors\":\"Adeniyi Ayinde Abdulwahab, Ukamaka Gladys Okafor, Damilola Samuel Adesuyi, Adriana Viola Miranda, Rashidat Onyinoyi Yusuf, Don Eliseo Lucero-Prisno III\",\"doi\":\"10.1002/hcs2.117\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n <p>In response to the situation of the African healthcare system, the African Medicines Agency (AMA) was established by the African Union (AU) to regulate access to medicines and support the local manufacture of medications. This study aimed to describe the factors that enabled the establishment of the African Medicines Agency and its successes, challenges, and perceived benefits. We reviewed data sources that explored the progress and challenges of the African Medicines Agency and Medicines Regulation in Africa. The SPIDER framework was used to organise the research focus and to extract the keywords for the literature search. The study data were obtained from PubMed Central, ScienceDirect, and Google Scholar. Out of 249 studies screened, 19 were selected for this narrative review. Critical successes observed in the agency's establishment include the appointment of a Special Envoy, the selection of its headquarters, and the signing of its treaty by 37 member states. However, it is hindered by poor political commitment, differences in risk-benefits interpretation and organizational structure, weak legal and regulatory frameworks, inadequate financial mechanisms, and inadequate political and policy leadership in some member states. The value of AMA in achieving optimal health outcomes and its other benefits must be considered despite the challenges being encountered. Therefore, all member states should adopt the best procedures in signing and ratifying the treaty and implementing associated commitments to improve efficiency and accountability in African medicine regulation.</p>\\n </section>\\n </div>\",\"PeriodicalId\":100601,\"journal\":{\"name\":\"Health Care Science\",\"volume\":\"3 5\",\"pages\":\"350-359\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-10-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11520252/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Health Care Science\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/hcs2.117\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health Care Science","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hcs2.117","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
为应对非洲医疗保健系统的状况,非洲联盟(AU)成立了非洲药品管理局(AMA),以规范药品的获取并支持药品的本地生产。本研究旨在描述促成非洲药品管理局成立的因素及其成功之处、面临的挑战和感知到的益处。我们审查了探讨非洲药品管理局和非洲药品监管进展与挑战的数据来源。我们使用 SPIDER 框架来组织研究重点,并为文献检索提取关键词。研究数据来自 PubMed Central、ScienceDirect 和 Google Scholar。在筛选出的 249 项研究中,有 19 项被选中用于本叙述性综述。该机构在建立过程中取得的重大成就包括任命了一名特使、选定了总部以及 37 个成员国签署了条约。然而,政治承诺不足、风险效益解释和组织结构存在差异、法律和监管框架薄弱、财务机制不健全以及一些成员国的政治和政策领导力不足等因素阻碍了该机构的发展。尽管面临种种挑战,但必须考虑到 AMA 在实现最佳健康结果方面的价值及其他益处。因此,所有成员国都应采用最佳程序签署和批准该条约,并履行相关承诺,以提高非洲医药监管的效率和问责制。
The African Medicines Agency and Medicines Regulation: Progress, challenges, and recommendations
In response to the situation of the African healthcare system, the African Medicines Agency (AMA) was established by the African Union (AU) to regulate access to medicines and support the local manufacture of medications. This study aimed to describe the factors that enabled the establishment of the African Medicines Agency and its successes, challenges, and perceived benefits. We reviewed data sources that explored the progress and challenges of the African Medicines Agency and Medicines Regulation in Africa. The SPIDER framework was used to organise the research focus and to extract the keywords for the literature search. The study data were obtained from PubMed Central, ScienceDirect, and Google Scholar. Out of 249 studies screened, 19 were selected for this narrative review. Critical successes observed in the agency's establishment include the appointment of a Special Envoy, the selection of its headquarters, and the signing of its treaty by 37 member states. However, it is hindered by poor political commitment, differences in risk-benefits interpretation and organizational structure, weak legal and regulatory frameworks, inadequate financial mechanisms, and inadequate political and policy leadership in some member states. The value of AMA in achieving optimal health outcomes and its other benefits must be considered despite the challenges being encountered. Therefore, all member states should adopt the best procedures in signing and ratifying the treaty and implementing associated commitments to improve efficiency and accountability in African medicine regulation.